These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23989720)

  • 21. Gene therapy for heart failure.
    Thompson RB; Rungwerth K; Koch WJ
    Ann Med; 2004; 36 Suppl 1():106-15. PubMed ID: 15176432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure.
    Papolos A; Frishman WH
    Cardiol Rev; 2013; 21(3):151-4. PubMed ID: 23568057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene Therapy in Heart Failure.
    Fargnoli AS; Katz MG; Bridges CR; Hajjar RJ
    Handb Exp Pharmacol; 2017; 243():395-421. PubMed ID: 27796512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac gene therapy with SERCA2a: from bench to bedside.
    Gwathmey JK; Yerevanian AI; Hajjar RJ
    J Mol Cell Cardiol; 2011 May; 50(5):803-12. PubMed ID: 21093451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hopes for gene therapy for cardiac failure].
    Prunier F; Hajjar RJ
    Arch Mal Coeur Vaiss; 2006 Jan; 99(1):41-7. PubMed ID: 16479888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene therapy for heart failure.
    Njeim MT; Hajjar RJ
    Arch Cardiovasc Dis; 2010; 103(8-9):477-85. PubMed ID: 21074127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling.
    Miyazaki Y; Ikeda Y; Shiraishi K; Fujimoto SN; Aoyama H; Yoshimura K; Inui M; Hoshijima M; Kasahara H; Aoki H; Matsuzaki M
    PLoS One; 2012; 7(4):e35875. PubMed ID: 22558250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene delivery approaches to heart failure treatment.
    Schroder JN; Williams ML; Koch WJ
    Expert Opin Biol Ther; 2004 Sep; 4(9):1413-22. PubMed ID: 15335309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.
    Kawase Y; Ly HQ; Prunier F; Lebeche D; Shi Y; Jin H; Hadri L; Yoneyama R; Hoshino K; Takewa Y; Sakata S; Peluso R; Zsebo K; Gwathmey JK; Tardif JC; Tanguay JF; Hajjar RJ
    J Am Coll Cardiol; 2008 Mar; 51(11):1112-9. PubMed ID: 18342232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
    Jessup M; Greenberg B; Mancini D; Cappola T; Pauly DF; Jaski B; Yaroshinsky A; Zsebo KM; Dittrich H; Hajjar RJ;
    Circulation; 2011 Jul; 124(3):304-13. PubMed ID: 21709064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.
    Penny WF; Hammond HK
    Hum Gene Ther; 2017 May; 28(5):378-384. PubMed ID: 28322590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene therapy for heart failure.
    Tilemann L; Ishikawa K; Weber T; Hajjar RJ
    Circ Res; 2012 Mar; 110(5):777-93. PubMed ID: 22383712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy targeted at calcium handling as an approach to the treatment of heart failure.
    Hoshijima M
    Pharmacol Ther; 2005 Mar; 105(3):211-28. PubMed ID: 15737405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential future therapies for heart failure: gene transfer of beta-adrenergic signaling components.
    Maurice JP; Koch WJ
    Coron Artery Dis; 1999 Sep; 10(6):401-5. PubMed ID: 10474791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [SERCA2 as a cause and therapeutic target of heart failure].
    Arai M
    Nihon Yakurigaku Zasshi; 2012 Dec; 140(6):259-64. PubMed ID: 23229631
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.
    Zsebo K; Yaroshinsky A; Rudy JJ; Wagner K; Greenberg B; Jessup M; Hajjar RJ
    Circ Res; 2014 Jan; 114(1):101-8. PubMed ID: 24065463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiological mechanism and therapeutic role of S100 proteins in cardiac failure: a systematic review.
    Imbalzano E; Mandraffino G; Casciaro M; Quartuccio S; Saitta A; Gangemi S
    Heart Fail Rev; 2016 Sep; 21(5):463-73. PubMed ID: 26833319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered sarco(endo)plasmic reticulum calcium adenosine triphosphatase 2a content: Targets for heart failure therapy.
    Liu G; Li SQ; Hu PP; Tong XY
    Diab Vasc Dis Res; 2018 Jul; 15(4):322-335. PubMed ID: 29762054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SERCA2a: a prime target for modulation of cardiac contractility during heart failure.
    Park WJ; Oh JG
    BMB Rep; 2013 May; 46(5):237-43. PubMed ID: 23710633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides.
    Zhai Y; Luo Y; Wu P; Li D
    J Med Genet; 2018 May; 55(5):287-296. PubMed ID: 29478009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.